Eli Lilly (NYSE: LLY) has released compelling efficacy results from a Phase III study evaluating its GLP-1 receptor agonist, tirzepatide, in adults with obesity or overweight accompanied by comorbidities, excluding type 2 diabetes (T2D). The study successfully met its two co-primary endpoints, demonstrating superiority over placebo in weight loss after 84 weeks, which included a 12-week lead-in period to ensure participants were responsive to intensive lifestyle interventions.
Significant Weight Loss Achieved
The treatment-regimen estimand results, which estimate the average treatment effect regardless of whether participants discontinued treatment, showed an impressive 21.1% mean weight loss in the experimental arm. This was in stark contrast to a 3.3% weight gain observed in the placebo group. Furthermore, 94.4% of participants receiving tirzepatide achieved a weight reduction of 5% or more, a significant milestone in weight management, compared to only 10.7% in the control group.
Safety Profile and Adverse Events
While the efficacy of tirzepatide was notable, the study also reported that adverse events led to treatment discontinuation in 10.5% of patients taking the drug, a rate significantly higher than the 2.1% observed with placebo. This highlights the ongoing balance between the drug’s effectiveness and its safety profile, a critical consideration in the development and application of new obesity treatments.-Fineline Info & Tech
